The patent expiries of Merck & Co. Inc. 's $4.4 billion simvastatin (Zocor) and Pfizer Inc. 's $2.6 billion anti-depressant sertraline (Zoloft) within a week in June prompted the Big Pharmas to fight back with their own low-cost versions. Generics are becoming too large, and important, to resist--after all, they have the world's payers on their side.
Generics firms also have more financing options. Last month, Paul Capital Partners, through its Paul Royalty Fund, agreed to invest...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?